KDM1A, a potent and selective target, for the treatment of DNMT3A-deficient non-small cell lung cancer. Zhao Y, Zheng Y, Fu J, Zhang J, et al. Br J Cancer 2024 Jun 29. doi: 10.1038/s41416-024-02772.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Zhao Y, Zheng Y, Fu J, Zhang J, et al. KDM1A, a potent and selective target, for the treatment of DNMT3A-deficient non-small cell lung cancer. Br J Cancer 2024 Jun 29. doi: 10.1038/s41416-024-02772.
PMID: 38951697